Discussion
Treatment with Uplizna (inebilizumab-cdon) was associated with fewer attacks and reduced disability in Chinese adults with neuromyelitis optica spectrum disorder (NMOSD) who have anti-aquaporin-4 (AQP4) antibodies, a real-world study found. The estimated one-year attack-free rate was 95.5%. According to the researchers, the findings “provided evidence on the real-world…